If you are considering the ChondroFiller injection for joint wear, one of the most important questions to ask early is whether you are actually a suitable candidate. Getting that assessment right is the foundation of realistic expectations and good outcomes. This article sets out the clinical factors that may make the injection unsuitable, and briefly describes what other options exist for those who do not qualify.

When the ChondroFiller Injection May Not Be Suitable

ChondroFiller is a CE-marked Class III acellular type I collagen scaffold that is delivered as a non-surgical, ultrasound-guided outpatient injection. It works by providing a regenerative matrix that recruits the patient's own progenitor cells to support cartilage repair. Because it relies on a functional local joint environment to be effective, certain conditions can undermine that process or raise safety concerns.

The following are among the situations where the injection is generally considered unsuitable:

• Advanced or generalised osteoarthritis — when joint wear is widespread rather than focal, the scaffold has little intact tissue to work with and the biological environment is unlikely to support meaningful repair.
• Inflammatory joint disease — conditions such as rheumatoid arthritis or psoriatic arthritis involve active immune-mediated inflammation that can disrupt the joint environment and interfere with the scaffold's integration.
• Active infection in or around the joint — any local or systemic infection is a contraindication; introducing a biologic device into an infected joint carries significant risk.
• Tumours near the joint — the presence of a tumour in the vicinity makes injection inadvisable.
• Pregnancy — as with most injectable biologic therapies, the procedure is avoided during pregnancy in the absence of safety data.
• Very extensive cartilage damage — if the defect is too large, too deep, or affects the underlying bone significantly, the injection alone is unlikely to be sufficient.

These are not exhaustive. Clinician judgement is always required, as individual circumstances vary considerably.

Patient Factors: Age, Weight, and Overall Joint Health

Beyond underlying conditions, personal factors also influence whether the ChondroFiller injection is likely to be beneficial. The device is intended for localised focal defects and joint wear rather than diffuse degeneration, so the nature and extent of the wear matters as much as a patient's age or weight.

Body weight has a bearing on load-bearing joints such as the knee and hip; significant excess weight increases mechanical stress on a treated site and may affect how well the scaffold beds in and supports repair. Age alone is not a bar — the injection has been used across a broad age range — but older patients with more advanced background degeneration may see more limited benefits. Honest, individualised assessment is essential.

Clinical Assessment and Imaging

Determining whether the ChondroFiller injection is appropriate requires a careful clinical evaluation. This typically involves a detailed history and examination to understand the pattern, duration, and severity of symptoms, followed by imaging — most commonly an MRI — to judge the extent and localisation of cartilage wear, the state of the surrounding joint surfaces, and whether there is any involvement of the underlying bone.

The imaging findings inform the decision in two directions: they can confirm that a patient has a focal, accessible defect suitable for the injection, or they may reveal that the damage is too extensive or involves bone loss, which would point towards a different approach.

When the Injection Is Not the Right Fit: Understanding the Surgical Alternative

Patients who are not suitable for the ChondroFiller injection — typically those with larger defects, involvement of the underlying bone, or load-bearing sites where the injection route alone is insufficient — may instead be candidates for the Liquid Cartilage protocol.

Liquid Cartilage is a distinct surgical procedure, not an alternative name for the injection. It is Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical protocol that delivers the ChondroFiller scaffold directly to the defect site under direct vision, combined with biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own mesenchymal stem cells derived from bone-marrow concentrate or micro-fragmented fat. It involves a theatre setting, anaesthetic, and a structured rehabilitation programme. The surgical approach is suited to larger or more complex defects in the knee, hip, shoulder, or ankle where the outpatient injection route would be insufficient.

It is important to understand this distinction: ChondroFiller is the CE-marked collagen scaffold material; the injection delivers it non-surgically; Liquid Cartilage is the surgical protocol that uses the same material with additional biological augmentation. They are not the same thing, and the choice between them depends on clinical assessment.

Other Options for Those Unsuitable for Either Pathway

For patients who are not suitable for either the injection or the surgical protocol, a range of other management strategies may be appropriate. Conservative measures — physiotherapy, weight management, activity modification, and simple analgesics — remain valuable for symptom control at all stages of joint disease. Other injection options, such as hyaluronic acid or platelet-rich plasma, may provide symptom relief in early osteoarthritis, though they work through different mechanisms. At the more severe end, joint replacement surgery may ultimately be the most appropriate option when structural damage is too advanced for biologic or regenerative approaches.

The right choice always depends on the degree and pattern of wear, overall health, activity level, and individual priorities — and is best arrived at through shared decision-making with a specialist.

Conclusion

The ChondroFiller injection is not suitable for every patient. Those with advanced arthritis, active infection, inflammatory joint disease, pregnancy, or very extensive cartilage damage may be better served by other approaches — whether that is conservative management, the Liquid Cartilage surgical protocol, or eventually joint replacement. It is not a cure for arthritis, and realistic expectations are important. If you would like a personalised assessment of which pathway might suit your situation, the London Cartilage Clinic on Harley Street offers specialist evaluation.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.